

### 25 Abstract



*aeruginosa* genomes and metagenomes will improve AMR identification, addressing a critical facet in<br>
49 combatting this treatment-refractory pathogen. However, knowledge gaps remain in our<br>
49 understanding of the *P. aer* 

- 49 combatting this treatment-refractory pathogen. However, knowledge gaps remain in our
- 50 understanding of the *P. aeruginosa* resistome, particularly the basis of colistin AMR.<br>2

### 51 Background



- quare are demonstrate far exceeds the performance to current AMR prediction software, provides a crucial steppingstone towards the routine clinical use of genomics and metagenomics to inform personalised *P. aeruginosa* an
- 78 performance to current AMR prediction software, provides a crucial steppingstone towards the
- routine clinical use of genomics and metagenomics to inform personalised *P. aeruginosa* antimicrobial<br>180 treatment regimens.<br>180 treatment regimens.
- 80 treatment regimens.

### 81 Methods

- **P. aeruginosa AMR variant database construction**. To cover the spectrum of AMR variants found in *P.*<br>
aeruginosa, an ARDaP v1.9 [14] compatible SQLite database was populated with all known AMR<br>
variants described in this
- 
- 84 variants described in this pathogen to date
- 85 (https://github.com/dsarov/ARDaP/blob/master/Databases/Pseudomonas\_aeruginosa\_pao1/). Gene
- 86 names, locus tags, and genomic coordinates in our AMR variant database were based on PAO1
- oeruginosa, an ARDaP v1.9 [14] compatible SQLite database was populated with all known AMR<br>84 variants described in this pathogen to date<br>85 <u>(https://github.com/dsarov/ARDaP/blob/master/Databases/Pseudomonas aeruginosa pa</u> 87 (NC\_002516.2) [18]. An exhaustive literature search was conducted to encompass biomedical
- 88 literature published from 1980 to April 20<sup>th</sup> 2023 within the MEDLINE database. Search terms included
- 
- 90 literature, and included either: i) antibiotic class (e.g. carbapenem, aminoglycoside); ii) AMR
- %89 "antimicrobial resistance" and "*P. aeruginosa"* accompanied by a variable search term for targeted<br>
90 literature, and included either: i) antibiotic class (e.g. carbapenem, aminoglycoside); ii) AMR<br>
91 mechanism (e.g mechanism (e.g. efflux, gene expression enzymatic inactivation); or iii) a known AMR gene (e.g. *oprD, ampC, gyrA*).<br>
92 am*pC, gyrA*).<br>
93 The resultant *P. aeruginosa* AMR database (Dataset 1) consists of three tables. T
- 92 *ampC, gyrA*).<br>93 The resultant<br>94 Antibiotics', li<br>95 cefepime, cef
- 
- The resultant *P. aeruginosa* AMR database (Dataset 1) consists of three tables. The first table, '1.<br>
94 Antibiotics', lists the ten clinically relevant antibiotics that were interrogated in our study: amikac<br>
95 cefepime 94 Antibiotics', lists the ten clinically relevant antibiotics that were interrogated in our study: amikacin,
- 95 cefepime, ceftazidime, ciprofloxacin, colistin, imipenem, meropenem, piperacillin,
- 96 piperacillin/tazobactam, and tobramycin, whether these drugs are first-line, second-line or tertiary,

97 and their associated antibiotic class. The second ('2. Variants SNP indel') and third ('3. Coverage')

tables list the entire *P. aeruginosa* mutational resistome [19, 20], which includes all known genetic<br>alterations that can lead to AMR, including the functional loss of chromosomal genes (under, '3.<br>Coverage'). These data

- 99 alterations that can lead to AMR, including the functional loss of chromosomal genes (under, '3.
- 100 Coverage'). These databases include all AMR variants and genes that: i) cause efflux pump

101 upregulation [21]; ii) alter outer membrane permeability [22]; iii) de-repress or alter the substrate

102 range of the AmpC cephalosporinase [23]; and/or iv) alter the antimicrobial target [24]. AMR gene

103 acquisition was interrogated with ResFinder v4.0 [25], using default parameters and retaining only

104 genes identified at 100% similarity and with 100% coverage. Resfinder is integrated within the ARDaP

- 105 tool and run as part of the default pipeline. The default ResFinder database was manually curated to:
- 106 1) remove false-positive hits that were consistently identified in AMR sensitive strains;  $bla_{\rm OXA}$ - $\frac{1}{5}$

107 <sub>395\_1\_AY306133</sub>, *bla*<sub>OXA-396\_1</sub>\_AY306134, *bla*<sub>PAO\_4</sub>\_AY083592, *bla*<sub>PAO\_1</sub>\_AY083595, *bla*<sub>PAO\_3\_FJ666073, *bla*<sub>PAO\_2</sub>\_FJ666065, and<br>108 crpP\_HM560971; 2) include additional gene variants identified within the </sub>

- 
- 108 crpP\_HM560971; 2) include additional gene variants identified within the Global Dataset in<br>
109 aminoglycoside AMR-conferring genes  $aac(6')$ -lb,  $aac(6')$ -lla,  $aac(6')$ -lb-cr, and  $aac(3)$ -llla; an<br>
110 ResFinder recommendatio 109 aminoglycoside AMR-conferring genes  $aac(6')$ -Ib,  $aac(6')$ -Ila,  $aac(6')$ -Ib-cr, and  $aac(3)$ -Illa; and 3) as per<br>110 ResFinder recommendations for *P. aeruginosa*, the substrate range for  $bla_{\text{OXA-2,1\_DQ112222}}$  and  $bla_{\text{OXA}}$
- 110 ResFinder recommendations for *P. aeruginosa*, the substrate range for  $bla_{\text{OXA-2\_1\_DQ112222}}$  and  $bla_{\text{OXA-2\_2\_QQ466184}}$  was expanded to include meropenem and imipenem.<br>112 For the aminoglycosides (i.e. amikacin and

111 2\_2\_GQ466184 was expanded to include meropenem and imipenem.

- 112 For the aminoglycosides (i.e. amikacin and tobramycin), known AMR variants consisted of point
- 
- 113 mutations in *algA* [26], *amgS* [27], *fusA1* [26, 28-33], *rplB* [34], *ptsP* [33, 35], and *tuf1* [26], and loss-of-<br>114 function mutations in the *nuo* [36-38] pathway. For the carbapenems (i.e. imipenem and merop 114 function mutations in the *nuo* [36-38] pathway. For the carbapenems (i.e. imipenem and meropenem),<br>
115 cephalosporins (i.e. ceftazidime), and β-lactams with or without an inhibitor (i.e. piperacillin and<br>
116 piper

115 cephalosporins (i.e. ceftazidime), and β-lactams with or without an inhibitor (i.e. piperacillin and

- 
- piperacillin/tazobactam), mutations that alter or expand the substrate range of the *ampC*<br>cephalosporinase [23, 39-42] or that alter *ampC* expression, including inactivation of penic<br>binding-protein 4 (PBP4; *dacB*) [43-
- cephalosporinase [23, 39-42] or that alter *ampC* expression, including inactivation of penicillin-<br>
binding-protein 4 (PBP4; *dacB*) [43-45], *ampD* [45-47], *ampDh2* [47], *ampDh3* [47], *ampE* [47],<br>
[48, 49], *mpl* [50 inding-protein 4 (PBP4; dacB) [43-45], ampD [45-47], ampDh2 [47], ampDh3 [47], ampE [47], ampR<br>
119 [48, 49], mpl [50], or ampC-ampR intergenic region [51], mutations in PBP3 (ftsl) [48, 52, 53], and<br>
120 mutations that ca
- [48, 49], *mpl* [50], or *ampC-ampR* intergenic region [51], mutations in PBP3 (*ftsI*) [48, 52, 53], and<br>
120 mutations that cause *oprD* loss, inactivation, or down-regulation [49, 54-60], were included. For<br>
121 ciprofl

mutations that cause *oprD* loss, inactivation, or down-regulation [49, 54-60], were included. For<br>
121 ciprofloxacin AMR prediction, we included point mutations in *gyrA* [61-67], *gyrB* [62, 63, 65, 68],<br>
122 [61-63, 66]

121 ciprofloxacin AMR prediction, we included point mutations in gyrA [61-67], gyrB [62, 63, 65, 68], parC<br>
122 [61-63, 66], and parE [62, 63, 65]. For colistin AMR prediction, point mutations in *cprS* [52], pmrA [69],<br>
1 122 [61-63, 66], and *parE* [62, 63, 65]. For colistin AMR prediction, point mutations in *cprS* [52], *pmrA* [69],<br>
123 pmrB [31, 69-74], *phoP* [69], and *phoQ* [69] were included.<br>
124 Efflux pumps play a key role in AM 123 *pmrB* [31, 69-74], *phoP* [69], and *phoQ* [69] were included.<br>
124 Efflux pumps play a key role in AMR development in *P. aeru*<br>
125 alterations, which drive efflux pump overexpression [15]. To<br>
126 is associated w Efflux pumps play a key role in AMR development in *P. aeruginosa*, predominantly through regulator<br>125 alterations, which drive efflux pump overexpression [15]. To predict MexAB-OprM upregulation, whic<br>126 is associated 125 alterations, which drive efflux pump overexpression [15]. To predict MexAB-OprM upregulation, which 126 is associated with β-lactam (including carbapenem) AMR [21], we included mutations in the *cis (mexR*<br>127 [29, 61, 64, 75, 76]) and *trans (nalC* [77, 78] and *nalD* [23, 71, 77-79]) regulators of this efflux pump.<br>12 127 [29, 61, 64, 75, 76]) and *trans* (*nalC* [77, 78] and *nalD* [23, 71, 77-79]) regulators of this efflux pump.<br>
128 For MexCD-OprJ upregulation, which is associated with fluoroquinolone and specific β-lactam AMR<br>
129 128 For MexCD-OprJ upregulation, which is associated with fluoroquinolone and specific β-lactam AMR 129 [21], mutations and loss-of coverage in the single known regulator, *nfxB* [61, 64] were included. For<br>130 MexEF-OprN upregulation, which is linked to fluoroquinolone AMR [21], we included function-alteri<br>131 mutation 130 MexEF-OprN upregulation, which is linked to fluoroquinolone AMR [21], we included function-altering 131 mutations or loss of coverage in *mexS* [80], the LysR family regulator *mexT* [81], and the global regulator *mvaT* [82]. For MexXY upregulation, which is associated with aminogly coside and  $6$ 132 regulator  $m$ vaT [82]. For MexXY upregulation, which is associated with aminoglycoside and<br>6

133 fluoroquinolone AMR, we included loss-of-coverage in two refined regions of *mexZ* [83, 84] and the<br>134 intergenic region (*mexOZ*) between *mexZ* and *mexX* [85, 86]. Additionally, functional gene loss varial<br>135 acro intergenic region (*mexOZ*) between *mexZ* and *mexX* [85, 86]. Additionally, functional gene loss variants<br>across the entire *P. aeruginosa* chromosome, identified via transposon insertion experiments [36, 38,<br>87], were i across the entire *P. aeruginosa* chromosome, identified via transposon insertion experiments [36, 38,<br>
136 87], were included.<br>
137 In addition to variants that confer AMR, mutations in essential AMR-conferring genes that 136 87], were included.

137 In addition to variants that confer AMR, mutations in essential AMR-conferring genes that cause

unusual antimicrobial susceptibility were included: efflux pumps *mexAB* [88, 89], *mexXY* [90], *mexCD*<br>[91] and *mexEF* [82, 92], and the *ampC* regulators *ampP* and *ampG*, which are required for high-level<br>*ampC* expr 139 [91] and *mexEF* [82, 92], and the *ampC* regulators *ampP* and *ampG*, which are required for high-level<br>
140 *ampC* expression [51]. We also included additional targets for (meta)genome quality control and *P*.<br>
141

ampC expression [51]. We also included additional targets for (meta)genome quality control and P.<br>
141 aeruginosa speciation (ecfX [93]), and genes responsible for conferring a hypermutator phenotype<br>
142 (mutS, mutL and u

141 *aeruginosa* speciation (*ecfX* [93]), and genes responsible for conferring a hypermutator phenotype<br>
142 (*mutS, mutL* and *uvrD* [94]).<br> **143 Global Dataset**. To comprehensively capture geographic, genomic, and ph 142 (*mutS, mutL* and *uvrD* [94]).<br>143 **Global Dataset**. To compreh<br>144 collated a large and comprel<br>145 strains with paired antimicro 143 **Global Dataset.** To comprehensively capture geographic, genomic, and phenotypic diversity, we<br>144 Collated a large and comprehensive *P. geruginosg* isolate collection (*n*=1877) of all publicly available collated a large and comprehensive *P. aeruginosa* isolate collection (*n*=1877) of all publicly available<br>145 strains with paired antimicrobial phenotype and genomic data [9, 20, 32, 54, 95-103] (Dataset 2, Tab<br>146 S1). T 145 strains with paired antimicrobial phenotype and genomic data [9, 20, 32, 54, 95-103] (Dataset 2, Table 146 S1). This dataset includes many antimicrobial-susceptible strains, which are essential for developing 147 and refining high-quality AMR databases [14, 104]. Isolates with minimum inhibitory concentration 148 (MIC) data were reclassified as sensitive, intermediate, or resistant using the CLSI M100S-Ed32:2022 149 guidelines.

**150** Validation Dataset. To independently evaluate AMR software performance, we examined 102<br>151 phylogenetically diverse, analysis-naïve, clinical *P. aeruginosa* strains (Figures S1 and S2). Isolates were

phylogenetically diverse, analysis-naïve, clinical *P. aeruginosa* strains (Figures S1 and S2). Isolates were<br>152 obtained from people admitted to hospitals in Qld, Australia, with cystic fibrosis (CF; *n*=42),<br>153 bactera

152 obtained from people admitted to hospitals in Qld, Australia, with cystic fibrosis (CF; *n*=42),<br>
153 bacteraemia (*n*=35), chronic obstructive pulmonary disease (COPD; *n*=21), bronchiectasis (*n*<br>
154 infection (*n* 

155 four isolates have previously been genome-sequenced (NCBI BioProject PRJNA761496; GenBank

bacteraemia (*n*=35), chronic obstructive pulmonary disease (COPD; *n*=21), bronchiectasis (*n*=1), ear<br>154 infection (*n*=1), ulcer (*n*=1), or urinary tract infection (*n*=1), between 2008 and 2020 (Table S2). Eight<br>155 infection (*n*=1), ulcer (*n*=1), or urinary tract infection (*n*=1), between 2008 and 2020 (Table S2). Eighty-<br>155 four isolates have previously been genome-sequenced (NCBI BioProject PRJNA761496; GenBank<br>156 accessions N 156 accessions NSXK00000000.1 and NSZK00000000.1) and some have previously undergone antimicrobial

157 susceptibility testing [105, 106]. For the current study, 18 additional COPD isolates (SCHI0038.S.1,

158 SCHI0050.S.3, SCHI0058.S.1, SCHI0058.S.2, SCHI0059.S.1, SCHI0064.S.1, SCHI0065.S.1, SCHI0068.S.3,



- 160 SCHI0109.S.2, SCHI0112.S.1, SCHI0112.S.2) were sequenced and appended to BioProject
- 161 PRJNA761496. Antimicrobial susceptibility profiles for 8 of 10 clinically-relevant antibiotics were
- 162 determined across the Validation Dataset (Table S2) using disc diffusions, following CLSI M100S-
- 163 Ed32:2022 guidelines. Meropenem and ciprofloxacin MICs were determined by ETEST (bioMérieux,
- 164 Murarrie, Australia) using sensitive, intermediate, and resistant MIC cut-offs of ≤4, 8, and ≥16 µg/mL
- 165 for meropenem, and ≤0.5, 1, and ≥2 µg/mL for ciprofloxacin. PAO1 (Belgian Coordinated Collection of
- 166 Microorganisms [BCCM], Ghent University, Belgium) and LMG 6395 (BCCM) were included as
- 167 antimicrobial-susceptible controls.

## 168 Microbial genome-wide association study (mGWAS) and machine learning (ML) for AMR prediction.<br>169 To identify novel AMR variants, mGWAS [107] was performed on the Global *P. aeruginosa* Dataset

169 To identify novel AMR variants, mGWAS [107] was performed on the Global *P. aeruginosa* Dataset<br>170 (n=1877 strains), with SNPs and indels identified using SPANDx v4.0.1 [108]. To increase the signal-<br>171 noise ratio, (n=1877 strains), with SNPs and indels identified using SPANDx v4.0.1 [108]. To increase the signal-to-<br>
noise ratio, variants found in antimicrobial-sensitive isolates were penalised four-fold compared with<br>
AMR strains d

171 noise ratio, variants found in antimicrobial-sensitive isolates were penalised four-fold compared with

172 AMR strains due to a presumed large effect size [109]. The top 50 variants associated with each AMR

173 phenotype were assessed for their ability to improve phenotype prediction; those that improved

174 phenotype prediction were included in the AMR database. Additionally, a supervised ML approach was

175 performed using the Global Dataset and the AMR database as features for model creation.

176 Comparative genomic analysis. To identify additional novel AMR variants, we conducted a<br>177 comparative genomic analysis using SPANDx. with a focus on AMR strains that did not enco

comparative genomic analysis using SPANDx, with a focus on AMR strains that did not encode a known 178 AMR variant (i.e. false negatives). These strains were compared to their closest antimicrobial-sensitive 179 relative(s) as determined by the whole-genome phylogenetic analysis (**Figure S1**). SNPs and indels that<br>180 separated AMR from antimicrobial-sensitive strain/s were identified, annotated and investigated w 181 manual inspection to prioritise mutations in known AMR genes. Candidate variants were then tested 182 against the Global Dataset to determine whether they improved phenotype prediction. AMR variants 183 that increased balanced accuracy (bACC) were included in the database; those that did not alter, or 184 that decreased bACC, were discarded.

- 186 (v1.0), implemented in ARDaP [110]. ARDaP was chosen as it is the only AMR software that can detect
- **AMR prediction analysis.** AMR prediction was performed using our *P. aeruginosa* AMR database<br>186 (v1.0), implemented in ARDaP [110]. ARDaP was chosen as it is the only AMR software that can do<br>187 all mutation types (i.e 187 all mutation types (i.e. SNPs, indels, gene gain, gene loss, frameshift mutations, structural variants,
- 188 and CNVs) [14]. ARDaP also has a built-in feature that automatically generates a clinician-friendly
- 
- 190 interpretation [14]. ARDaP performance was compared against four tools for AMR phenotype
- antimicrobial susceptibility summary report for each strain (Figure S3) to simplify *in silico* AMR<br>190 interpretation [14]. ARDaP performance was compared against four tools for AMR phenotype<br>191 prediction and/or AMR var 191 prediction and/or AMR variant identification: abritAMR [111], RGI v5.1.0 and CARD v3.0.9 [11],
- 192 ResFinder v4.1 [10], and AMRFinderPlus v3.8.28 [112]. As abritAMR and AMRFinderPlus frequently
- 193 report predicted AMR phenotypes to the antibiotic class level only, we chose to interpret AMR variant
- 194 presence for a given class as conferring AMR towards all antibiotics within that class. Importantly,
- 195 AMRFinderPlus is not intended for clinical phenotype prediction
- 196 (https://github.com/ncbi/amr/wiki/Interpreting-results#genotype-vs-phenotype) but has been
- 197 included as a benchmark for gene detection accuracy. For the purposes of software comparisons, gene
- 198 identification by AMRFinderPlus was interpreted as conferring phenotypic resistance.

199 A variant scoring scheme has previously been described by Cortes-Lara and colleagues, which

- 
- 201 expanded upon this scheme by providing an automated weighted score for all AMR variants in our
- employed a 0 (no effect) through 1 (EUCAST AMR) scale to predict *in silico* AMR profiles [102]. We<br>201 expanded upon this scheme by providing an automated weighted score for all AMR variants in our<br>202 database that quant 202 database that quantifies their contribution, positive or negative, towards AMR development (Dataset
- 203 1, 'Threshold' column); this score is recorded for each antibiotic on ARDaP's automatically generated
- 204 clinician-friendly report (Figure S3), unlike the Cortes-Lara scheme, which requires manual scoring for
- 205 each antibiotic and strain [102]. Using our scoring system, variants known to cause AMR in isolation
- 206 score as 100%, whereas AMR variants known to confer AMR in a stepwise manner (that is, only when
- 207 in combination with other variant/s), or that only result in intermediate resistance, are given a lower
- 208 score (e.g. 40-50%). This method accounts for both the additive nature of chromosomal mutations in
- 209 P. aeruginosa, and for the decreased AMR potential caused by loss of efflux pumps or essential<br>g<br>9

- 210 transcriptional regulators. Acquired AMR genes identified by Resfinder within ARDaP were considered
- 211 to confer full AMR, i.e. are scored at 100% for the purposes of phenotype prediction.
- 212 Intermediate resistance prediction. The capacity of our AMR variant database to predict intermediate 213 resistance phenotypes was examined against the Global Dataset using the following criteria:
- 
- 214 A true-positive prediction occurred when either: i) an AMR strain was classed as AMR, or ii) an
- 215 intermediate strain was identified as intermediate;
- 216 A true-negative prediction occurred when an antimicrobial-sensitive strain was identified as 217 antimicrobial sensitive;
- 218 A false-positive prediction occurred when either: i) an antimicrobial-sensitive strain was
- 219 classed as intermediate or AMR, or ii) an intermediate strain was classed as AMR; and
- 220 A false-negative prediction occurred when either: i) an intermediate strain was classed as 221 antimicrobial-sensitive, or when an AMR strain was predicted to be antimicrobial-sensitive or 222 intermediate.
- 223 These rules provided the strictest evaluation criteria for the assessment of ARDaP's ability to identify 224 intermediate strains. Only ARDaP's intermediate resistance prediction performance was assessed as 225 abritAMR, AMRFinderPlus, CARD, and ResFinder all lack the capacity to identify intermediate 226 resistance.

**AMR software predictive performance in P. aeruginosa.** Due to its inability to predict AMR towards<br>228 individual antibiotics, and a very high rate of false-positive predictions in the Global Dataset. CARD w individual antibiotics, and a very high rate of false-positive predictions in the Global Dataset, CARD was deemed unsuitable for *P. aeruginosa* AMR analysis and was excluded from further assessment. For all<br>
230 other tools, predictive performance was determined using bACC [113, 114], which averages sensitivity<br>
231 [i.e. true 230 other tools, predictive performance was determined using bACC [113, 114], which averages sensitivity 231 [i.e. true positives/(true positives + false negatives)], and specificity [i.e. true negatives/(true negatives 232 + false positives)]. This metric was chosen as it accounts for dataset imbalance; that is, it minimises 233 over- or under- representation of antimicrobial-sensitive or AMR strains that may otherwise make 234 certain tools appear better or worse due to inherent dataset bias [8]. Additionally, we compared recall

- 235 (AMR) [true positives/(true positives + false negatives], precision (AMR) or positive predictive value
- 236 (PPV) [true positives/(true positives + false positives), recall (sensitivity) [true negatives/(true
- 237 negatives + false positives) and precision (sensitivity) or negative predictive value (NPV) [true
- 238 negatives/(true negatives + false negatives)] across all software tools.

239 Results

- **240 P. aeruginosa AMR variant identification and refinement.** An extensive literature search was<br>241 Undertaken to identify all known and putative chromosomal variants that lead to AMR in P.
- 
- 
- 243 classified as 'natural variation' as they were common in both antimicrobial-sensitive and AMR strains
- undertaken to identify all known and putative chromosomal variants that lead to AMR in *P.*<br>242 aeruginosa. Among the 733 identified chromosomal AMR variants, 284 putative variants we<br>243 classified as 'natural variation' or 242 aeruginosa. Among the 733 identified chromosomal AMR variants, 284 putative variants were<br>243 classified as 'natural variation' as they were common in both antimicrobial-sensitive and AMR<br>244 in our Global Dataset, 244 in our Global Dataset, and therefore deemed unlikely to contribute to an AMR phenotype. Most of
- 245 these naturally occurring variants had been previously reported as putatively causing AMR, with little
- 246 to no functional investigation. Importantly, no functionally validated AMR driving variants were re-
- 247 classified as 'natural variation'. Next, using mGWAS and comparative genomic analyses of the Global
- 248 Dataset, we identified 75 previously unreported AMR variants associated with one or more AMR
- 249 phenotypes (Table 2). In total, we identified 736 chromosomal variants in known AMR loci (Dataset 2),
- 250 of which 374 were associated with AMR and 284 were natural variation.
- **Predictive performance across Global Dataset.** Although superior to CARD, abritAMR, AMRFinderPlus, 252 and ResFinder still showed relatively poor bACCs for most antibiotics, with average bACCs of between
- and ResFinder still showed relatively poor bACCs for most antibiotics, with average bACCs of between
- 253 56 and 60%, well below ARDaP's average bACC of 85% (Figure 1A).
- 254 The best abritAMR, AMRFinderPlus, and ResFinder predictions were achieved for the aminoglycosides,
- 255 with average bACCs of 75%, 75%, and 82%, respectively, although these rates were lower than
- 
- 256 ARDaP's average aminoglycoside bACC of 92%. abritAMR, AMRFinderPlus, and ResFinder AMR<br>257 prediction for all other antibiotics showed poor to very poor bACCs. AMRFinderPlus had a bACC of just
- 258 50% for the penicillins, cephalosporins, and colistin the same predictive capacity as a coin flip and
- 259 had only a slightly better bACC for ciprofloxacin (58%), imipenem (58%), and meropenem (61%).

260 ResFinder also had a bACC of just 50% for cephalosporins and colistin, and performed worse for 261 carbapenems (average bACC of 50%) than AMRFinderPlus, although it was better for penicillins 262 (average bACC of 62%) and ciprofloxacin (bACC of 62%). abritAMR was the worst at predicting 263 penicillin phenotypes, with an average bACC of just 43%, worse than a coin flip; its performance was 264 otherwise identical to AMRFinderPlus. In contrast, ARDaP surpassed abritAMR, AMRFinderPlus, and 265 ResFinder across all 10 antibiotics, with bACCs ranging from 60% (colistin) to 94% (tobramycin) (Figure 266 1A).

**Predictive performance across Validation Dataset.** We next tested abritAMR, AMRFinderPlus, ARDaP,<br>268 and ResFinder across the Validation Dataset of 102 Australian clinical *P. aeruginosa* strains (Table S2)

269 to determine each software's performance in an analysis-naïve dataset. As no strains in the Validation

270 Dataset displayed colistin AMR, the bACC for this antibiotic could not be assessed. These strains

and ResFinder across the Validation Dataset of 102 Australian clinical *P. aeruginosa* strains (Table S2)<br>269 to determine each software's performance in an analysis-naïve dataset. As no strains in the Validatior<br>270 Datas 271 otherwise exhibited similar AMR rates to the Global Dataset, ranging from 26% for meropenem to 58%

272 for piperacillin (Table S4).

273 Overall, ARDaP had high predictive accuracy (average bACC of 81%) across all antibiotics (Figure 1B),

274 vastly outperforming ResFinder (average bACC of 53%), abritAMR, and AMRFinderPlus (average bACC 275 of 54% each). Notably, the ResFinder meropenem bACC, at just 43%, yielded worse performance than 276 a coin flip.

277 **Inclusion of the novel AMR variants identified in the Global Dataset.** The inclusion of these markers<br>278 increased Validation Dataset sensitivity by an average of 4% (range 0 to 27%) depending on antibiot

279 with the sensitivity of most antibiotics (meropenem, imipenem, ciprofloxacin, cefepime, and

280 piperacillin/tazobactam) remaining unchanged. Amikacin increased the most (27%) due to the

282 at 3% each."

inclusion of a SNP in *rplB* (Gly138Ser), followed by tobramycin at 4%, and piperacillin and ceftazidime<br>282 at 3% each."<br>**ARDaP performance between the Global and Validation Datasets.** Whilst ARDaP bACC between the<br>284 da 283 ARDaP performance between the Global and Validation Datasets. Whilst ARDaP bACC between the<br>284 datasets were broadly similar, there was a greater proportion of false-positive and false-negative datasets were broadly similar, there was a greater proportion of false-positive and false-negative

285 variants encoding AMR towards piperacillin (32% difference), tobramycin (24% difference), cefepime

- 286 (19% difference), amikacin (12% difference), and meropenem (9% difference) in the Validation
- 287 Dataset. In contrast, there was a greater proportion of false-positive and false-negative variants
- 288 encoding amikacin AMR (5% difference) in the Global Dataset (Figure 1).
- 289 Comparative genomic analysis of Validation Dataset isolates that yielded false-negative
- 290 aminoglycoside AMR predictions identified that many belonged to a single multilocus sequence type
- 291 (ST), ST801, also known as AUST-06. Among 23/24 aminoglycoside-AMR ST801 isolates, a clade-
- 
- 292 specific missense variant in elongation factor G (FusA1 S459F) was identified; this SNP was not<br>293 observed in other Global or Validation Dataset isolates. The remaining aminoglycoside-AMR ST<br>294 strain, SCHI0010.S.1, 293 observed in other Global or Validation Dataset isolates. The remaining aminoglycoside-AMR ST801
- 
- 295 S459F into our AMR database significantly increased ARDaP bACCs for the Validation Dataset by an
- 294 strain, SCHI0010.S.1, encoded *AAC*(6')-IIa, an aminoglycoside-modifying enzyme. Inclusion of FusA1<br>295 S459F into our AMR database significantly increased ARDaP bACCs for the Validation Dataset by an<br>296 average 19% f 296 average 19% for both amikacin and tobramycin, raising them to 95% and 90%, respectively, with no
- 
- 297 impact on Global Dataset bACC.<br>298 Precision and recall among AMR software. ARDaP demonstrated excellent precision and recall for
- 298 – **Precision and recall among AMR software.** ARDaP demonstrated excellent precision and recall for<br>299 – predicting antimicrobial-sensitive and AMR phenotypes, ranging from 73% (average AMR recall) to
- 300 96% (average sensitivity recall) (Figure 2A). In contrast, abritAMR ranged from 54% (average AMR
- 301 precision) to 62% (average sensitivity precision) (Figure 2B), AMRFinderPlus ranged from 54% (average
- 302 AMR precision) to 62% (average AMR recall) (Figure 2C), and ResFinder ranged from only 42% (average
- 303 AMR precision) to 68% (average sensitivity precision) (Figure 2D).

304 For colistin, abritAMR, AMRFinderPlus, and ResFinder all yielded AMR precision and recall values of 305 0%; in other words, none of these tools identified colistin AMR variants in strains exhibiting a colistin 306 AMR phenotype. In comparison, ARDaP identified colistin AMR strains with 21% recall and 100% 307 precision. Similarly, abritAMR, AMRFinderPlus, and ResFinder all failed to predict cefepime sensitivity 308 in any cefepime-sensitive strain (Figures 2B-2D), instead erroneously classing every strain as cefepime-309 resistant, whereas ARDaP correctly identified cefepime-sensitive strains with 96% precision and 96%

- 310 recall (Figure 2A). All three tools also failed to predict ceftazidime sensitivity. In addition, abritAMR
- 311 and AMRFinderPlus failed to identify piperacillin sensitivity in any of the tested strains, and
- 312 AMRFinderPlus yielded failed to identify piperacillin/tazobactam sensitivity (Figures 2B and 2C).<br>313 Predictive performance for intermediate resistance. The inclusion of isolates with intermediate
- 313 Predictive performance for intermediate resistance. The inclusion of isolates with intermediate<br>314 resistance reduced ARDaP bACCs by between 1 to 13% (6% average), depending on the antibiotic
- resistance reduced ARDaP bACCs by between 1 to 13% (6% average), depending on the antibiotic
- 315 (Table S5). Intermediate resistance inclusion was most detrimental to cefepime AMR prediction (-
- 316 13%), followed by imipenem (-8%), meropenem, ciprofloxacin and ceftazidime (-7%),
- 317 piperacillin/tazobactam and amikacin (-5%), piperacillin (-4%) and tobramycin (-1%). Colistin prediction
- 318 was unchanged as no intermediate category exists for this antibiotic.

### 319 Discussion



345 antibiotic phenotypes, and provides weighted scores on variant contribution towards AMR

347 which also found that CARD and ResFinder exhibited poor AMR prediction performance metrics across

348 all 11 tested anti-pseudomonal antibiotics [8].

development (Dataset 1). Our findings concur with a recent study of 654 *P. aeruginosa* genomes,<br>
347 which also found that CARD and ResFinder exhibited poor AMR prediction performance metrics a<br>
348 all 11 tested anti-pse 349 Although still inferior to ARDaP, abritAMR, AMRFinderPlus, and ResFinder performed best when 350 predicting aminoglycoside phenotypes in the Global Dataset (Figure 1A), which is heavily populated 351 with American and European strains (Table S1). These tools performed substantially worse when 352 tested against the Australian Validation Dataset (Figure 1B), with the average aminoglycoside bACC 353 dropping by 16% for AMRFinderPlus and 26% for ResFinder. ARDaP's bACC also initially dropped by 354 18% for the aminoglycosides. Upon closer inspection, we found that this performance reduction was 355 predominantly due to false-negative calls among the ST801 isolates, a geographically restricted clone that has only been reported in people with CF in Qld, Australia [116]. Inclusion of one novel *fusA1*<br>357 variant identified with comparative genomics in our AMR variant database restored ARDaP's<br>358 performance to bACC of 357 variant identified with comparative genomics in our AMR variant database restored ARDaP's 358 performance to bACC of 90% and 95% for amikacin and tobramycin, respectively. This performance 359 difference across isolate datasets can be attributed to two phenomena. The first is the predominance 360 of aminoglycoside-modifying enzymes in the Global (33%) but not Validation (8%) Datasets, reflecting 361 potential major differences in the geographic prevalence of these enzymes that requires further 362 exploration. The second is the enrichment of CF-derived isolates in the Validation Dataset, which 363 comprise 86% of the aminoglycoside AMR strains (Figure S1). These isolates have largely developed 364 aminoglycoside AMR via chromosomal mutation rather than aminoglycoside-modifying enzyme 365 acquisition; as such, abritAMR, AMRFinderPlus, and ResFinder exhibited poor aminoglycoside AMR 366 predictive capacity due to their limited chromosomal AMR variant databases. These performance 367 differences highlight the need for including isolates from diverse sources, disease states, and locales to 368 provide the most relevant AMR prediction software benchmarking comparisons. Our results suggest 369 that abritAMR, AMRFinderPlus, and ResFinder are not useful for predicting aminoglycoside AMR from

371 exploration across larger, geographically diverse datasets.



It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.08.11.22278689;](https://doi.org/10.1101/2022.08.11.22278689) this version posted October 31, 2023. The copyright holder for this preprint



increasing use of inhaled colistin in treatment-refractory, multidrug-resistant *P. aeruginosa* infections<br>
119, 120]<br>
1399 Loss-of-function mutations affecting the specialised porin, OprD, are the most common cause of<br>
14 Loss-of-function mutations affecting the specialised porin, OprD, are the most common cause of<br>
401 carbapenem AMR in *P. aeruginosa*, particularly in clinical isolates [9]. Although *oprD* is notorious<br>
402 hypervariable carbapenem AMR in *P. aeruginosa*, particularly in clinical isolates [9]. Although *oprD* is notoriously<br>
hypervariable [121], ARDaP's ability to accurately identify functional OprD loss accounted for its hig<br>
carbapenem p 402 hypervariable [121], ARDaP's ability to accurately identify functional OprD loss accounted for its high 403 carbapenem predictive accuracy (average bACC of 89% vs. just 61% for AMRFinderPlus and 52% for ResFinder). This outcome highlights the complex nature of the *P. aeruginosa* resistome, the necessity<br>of AMR variant curation efforts, the value of AMR prediction tools that can accurately detect the<br>spectrum of chromosom 405 of AMR variant curation efforts, the value of AMR prediction tools that can accurately detect the 406 spectrum of chromosomal variants, and the value of species-specific AMR variant databases to achieve 407 the most accurate AMR predictions.

A08 Mutations leading to chromosomal cephalosporinase (*ampC*) overexpression are an important cause<br>
of β-lactam AMR [15, 122]. To predict *ampC* upregulation, our database includes function-altering<br>
mutations in genes 409 of β-lactam AMR [15, 122]. To predict *ampC* upregulation, our database includes function-altering<br>410 mutations in genes known to directly or indirectly regulate *ampC*. These chromosomally-encoded<br>411 variants, alon mutations in genes known to directly or indirectly regulate *ampC*. These chromosomally-encoded<br>411 variants, alongside acquired cephalosporinases, accounted for the high average ARDaP bACC obse<br>412 for the cephalosporins 411 variants, alongside acquired cephalosporinases, accounted for the high average ARDaP bACC observed 412 for the cephalosporins (84% vs. just 50% with abritAMR, AMRFinderPlus, and ResFinder; Figure 1). The prominence of *ampC* over-expression-associated determinants provides further support that this<br>
414 mechanism is a major cause of acquired cephalosporin AMR, particularly in clinical *P. aeruginosa*<br>
415 isolates [122, 12 mechanism is a major cause of acquired cephalosporin AMR, particularly in clinical *P. aeruginosa*<br>415 isolates [122, 123]. In support of this hypothesis, Khaledi and colleagues demonstrated a consider<br>416 higher bACC for 415 isolates [122, 123]. In support of this hypothesis, Khaledi and colleagues demonstrated a considerably 416 higher bACC for ceftazidime AMR prediction when using both transcriptomic and genomic data (82%) 417 compared with just genomic data (67%) [9]. Genomics alone cannot currently identify all instances of *ampC* over-expression, either because up-regulation is the result of an epigenic change, or the<br>
mutation remains cryptic due to an incomplete understanding of *ampC* regulatory mechanisms<br>
Indeed, a review of intrinsic 419 mutation remains cryptic due to an incomplete understanding of <i>ampC</i> regulatory mechanisms. Indeed, a review of intrinsic β-lactamases by Juan and colleagues details the complexity of <i>ampC</i> expression and its intricate regulation, along with the challenge of corresponding elevated β-<br>421 expression and its intricate regulation, along with the challenge of corresponding elevated β-<br>421 420 Indeed, a review of intrinsic β-lactamases by Juan and colleagues details the complexity of *ampC*<br>421 expression and its intricate regulation, along with the challenge of corresponding elevated β-<br> $18$ 421 expression and its intricate regulation, along with the challenge of corresponding elevated β-

lactamase MICs driven by *ampC* upregulation to clinical AMR breakpoints [124]. Using a combination<br>of genomic and transcriptomic data will likely lead to further improvements in AMR prediction for<br>most antibiotics [9, 122 423 of genomic and transcriptomic data will likely lead to further improvements in AMR prediction for 424 most antibiotics [9, 122].

425 Predicting intermediate resistance is exceedingly difficult from genomic data alone, even with complex 426 machine learning algorithms that combine transcriptomic and genomic data [9]. We also encountered 427 difficulties in predicting intermediate resistance, with the inclusion of intermediate strains dropping 428 bACCs by up to 13% (Table S5). Possible explanations include the need to understand the contribution 429 of stepwise variants in conferring decreased antibiotic susceptibility [15, 67, 125], subtle and rapidly 430 reversible gene expression alterations [9] caused by methylation [126] or dynamic environmental 431 stimuli, and undetected strain mixtures. Further refinement of our ARDaP-compatible database, such 432 as capacity to analyse RNA-seq data, will continue to improve this critical yet understudied area. 433 Nevertheless, the pioneering capacity of ARDaP to predict intermediate resistance, including stepwise 434 mutations that lower the barrier to full AMR development, and to differentiate strain mixtures in 436 informing earlier treatment shifts [14].

metagenomic data, has important implications for detecting emerging AMR in *P. aeruginosa* and<br>
436 informing earlier treatment shifts [14].<br>
437 Errors introduced during sample collection, metadata curation, specimen proc 437 Errors introduced during sample collection, metadata curation, specimen processing, or sequencing 438 may be partially responsible for our inability to predict AMR with a 100% bACC for any antibiotic. For example, 11 strains in the Khaledi *et al*. dataset [9] possessed variants known to confer ceftazidime<br>
440 AMR (e.g. *bla<sub>VIM-[2,4,47]*, *bla<sub>OXA-2</sub>*, *bla<sub>GES-[1,5]*) yet were reported as ceftazidime-sensitive, and 22 s</sub></sub> AMR (e.g. *bla<sub>VIM-[2,4,47]*, *bla<sub>OXA-2</sub>*, *bla<sub>GES-[1,5]*) yet were reported as ceftazidime-sensitive, and 22 strains in<br>
441 the Kos *et al*. dataset were amikacin-sensitive, yet possessed the aminoglycoside-modifying </sub></sub> the Kos *et al.* dataset were amikacin-sensitive, yet possessed the aminoglycoside-modifying enzyme<br>gene  $aac(6')$ -lb-cr, known to cause amikacin AMR and reduced ciprofloxacin susceptibility [127]. Due<br>to the presence of thes gene *aac(6')-lb-cr*, known to cause amikacin AMR and reduced ciprofloxacin susceptibility [127]. Due<br>to the presence of these known AMR variants, all tools identified these strains as AMR, contributing t<br>imperfect bACC (F 443 to the presence of these known AMR variants, all tools identified these strains as AMR, contributing to 444 imperfect bACC (Figure 1) and poor precision (Figure 2) for amikacin and ceftazidime. As we did not 445 have access to these strains, it was not possible to retest their AMR phenotypes or to repeat genome 446 sequencing; however, we hypothesise that these strains would generate different results upon 447 phenotypic retesting or re-sequencing. Alternatively, these AMR variants may be present but

448 functionally or transcriptionally inactive, resulting in false-positive predictions for these isolates that

449 must be factored into future AMR prediction estimates.

450 We recognise several study limitations. First, some false-positive predictions were identified across all 451 antibiotic classes with our ARDaP-compatible database; however, these rates were significantly lower 452 than those reported by other software (Figure 1). Whilst not ideal, we chose to retain a small number 453 of AMR variants that result in low-frequency false-positive predictions as: i) some strains may have 454 reverted to a sensitive phenotype, despite encoding a known AMR variant; and ii) we included 455 phenotypic data generated by others, which may harbour inaccuracies. Functional profiling will be 456 essential to fully understand the contribution of each of these variants in conferring AMR. Second, 457 although we aimed for a phylogenetically diverse Validation Dataset (Figure S1, S2), only isolates from 458 Queensland, Australia, were included in this dataset, limiting geographic and genetic representation. 459 Despite this shortcoming, the Validation Dataset proved extremely useful for identifying AMR variant 460 database deficits across all three AMR tools, particularly those variants encoding AMR towards the 461 aminoglycosides, piperacillin, cefepime, and meropenem, highlighting clear areas of need for future 462 research efforts. Third, due to cost constraints, we only performed ciprofloxacin and meropenem 463 ETESTs for the Validation Dataset isolates, with disc diffusions used for the remaining eight antibiotics, 464 a less robust methodology that may have led to some minor discrepancies in antimicrobial phenotype assignments. Fourth, we did not test out ARDaP's capacity to identify *P. aeruginosa* AMR variants from<br>466 simulated and real metagenomic datasets and strain mixtures for this study as we have proven this<br>467 capacity els 466 simulated and real metagenomic datasets and strain mixtures for this study as we have proven this 467 capacity elsewhere [14, 106] nor were we able to compare software performance against ARESdb 468 [128] due to the proprietary nature of this database. Finally, our study would have benefitted from the 469 inclusion of transcriptomic data [9] to identify additional novel variants associated with AMR. Although our understanding of the molecular mechanisms of AMR in *P. aeruginosa* is improving rapidly in the<br>471 genomics era, false-negative predictions still occur across all antibiotic classes. Using ARDaP, such<br>472 false-negati 471 genomics era, false-negative predictions still occur across all antibiotic classes. Using ARDaP, such 472 false-negative strains can now be rapidly identified and targeted for future functional work to pinpoint 473 novel AMR variants and mechanisms.

### 474 Declarations



- 
- washing collection, and obtained study funding; SCB provided CF sputa that were used to retrieve P.<br>
500 aeruginosa isolates, and obtained ethics approval for sputum collection; KM provided bloodstream P<br>
501 aeruginosa is or seruginosa isolates, and obtained ethics approval for sputum collection; KM provided bloodstream P.<br>1901 aeruginosa isolates, and obtained ethics approval for blood collection; EPP assisted with study<br>1902 conception, o
- or *seruginosa* isolates, and obtained ethics approval for blood collection; EPP assisted with study<br>502 conception, obtaining and overseeing ethics approvals, manuscript preparation, data analyses<br>503 laboratory work, pro
- 502 conception, obtaining and overseeing ethics approvals, manuscript preparation, data analyses and
- 503 laboratory work, provided student supervision, obtained study funding, and assisted with curation of
- 504 the natural variant database; and DSS conceived and led the study, wrote the ARDaP software, refined
- the *P. aeruginosa* AMR variant database, assisted with manuscript preparation, data analyses and<br>
506 laboratory work, provided student supervision, and obtained study funding. All authors read and<br>
507 approved of the fi
- 506 laboratory work, provided student supervision, and obtained study funding. All authors read and
- 507 approved of the final manuscript.
- 
- 508 **Acknowledgements.** We wish to thank Jane Neill (Sunshine Coast Hospital and Health Service,<br>509 Sunshine Coast University Hospital) for providing the chronic obstructive pulmonary samples used in
- 510 this study, and Kay Ramsay (University of Queensland) and Tamieka Fraser (University of the Sunshine
- 511 Coast) for laboratory support.

### 512 References

















# 917 Tables<br>918 Table 1

## 918 Table 1. Summary of antimicrobial resistance prevalence across 10 clinically relevant antibiotics in<br>919 the *Pseudomonas aeruginosa* Global Dataset

### the Pseudomonas aeruginosa Global Dataset



920

921 Abbreviations: Res, resistant; Int, intermediate; Sen, sensitive; MEM, meropenem; IPM, imipenem;

922 CST, colistin; CIP, ciprofloxacin; FEP, cefepime; CAZ, ceftazidime, TZP, piperacillin/tazobactam; PIP,

923 piperacillin; TOB, tobramycin; AMK, amikacin

## 924 Table <mark>2. Nov</mark>el antimicrobial resistance (AMR) variants identified in *Pseudomonas aeruginosa* by<br>925 microbial genome-wide association study (mGWAS) or comparative genomic<sup>®</sup> analyses

## microbial genome-wide association study (mGWAS) or comparative genomic<sup>®</sup> analyses<br>





926 Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; fs,

927 frameshift; i, intermediate resistant; IPM, imipenem; LOF, loss of function; MEM, meropenem; NA, not

928 applicable; PIP, piperacillin; r, resistant; TOB, tobramycin; TZP, piperacillin/tazobactam

929 <sup>1</sup>Previously predicted to cause PIPr [129]; however, our microbial genome-wide associate study

PA5493 (polA) Lys395Arg<sup>®</sup> AMKr MAKR<br>Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; fs,<br>frameshift; i, intermediate resistant; IPM, imipenem; LOF, loss of function; MEM, m 930 (mGWAS) analysis did not identify a significant association with this phenotype. Instead, mGWAS

931 showed that this AMR variant was significantly associated with MEMr.

2 <sup>2</sup> Previously identified variant in *ampC* known to reduce susceptibility to multiple cephalosporins.<br>
<sup>2</sup> Previously identified by comparative genomics and thus not assessed for statistical significance.<br>
<sup>2</sup> <sup>2</sup> Prev 933 **Variant identified by comparative genomics and thus not assessed for statistical significance.** 

934 #Identified in the Validation Dataset only.

935 ^ High-consequence mutations occurring in this gene are automatically identified by ARDaP.



<sup>938</sup> Figure 1. Balanced accuracy of ARDaP, abritAMR, AMRFinderPlus, and ResFinder for antimicrobial<br>939 resistance (AMR) prediction in *Pseudomonas aeruginosa*. Software comparisons across ten clinicall<sup>,</sup> 939 **resistance (AMR) prediction in** *Pseudomonas aeruginosa***.** Software comparisons across ten clinically<br>940 relevant antibiotics were undertaken against (A) the Global Dataset (*n*=1877 isolates) and (B) th elevant antibiotics were undertaken against (A) the Global Dataset (n=1877 isolates) and (B) the<br>941 Validation Dataset (n=102 isolates). For both datasets, and for all 10 antibiotics, ARDaP outperfor<br>942 abritAMR, AMRFind Validation Dataset (n=102 isolates). For both datasets, and for all 10 antibiotics, ARDaP outperformed<br>
942 abritAMR, AMRFinderPlus, and ResFinder. To enable comparison with existing AMR prediction<br>
943 software, isolates 942 abritAMR, AMRFinderPlus, and ResFinder. To enable comparison with existing AMR prediction 943 software, isolates with intermediate AMR were removed prior to analysis. Abbreviations: AMK,

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.08.11.22278689;](https://doi.org/10.1101/2022.08.11.22278689) this version posted October 31, 2023. The copyright holder for this preprint

- 944 amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; FQs, fluoroquinolones; IPM,
- 945 imipenem; MEM, meropenem; PIP, piperacillin; TZP, piperacillin/tazobactam; TOB, tobramycin. \*No
- 946 strains in the Validation Dataset exhibited CST AMR; as such, balanced accuracy could not be



947 calculated for this antibiotic.

## 949 Figure 2. Precision and recall of ARDaP, abritAMR, AMRFinderPlus, and ResFinder across the Global<br>950 Dataset (n=1877 strains). Precision and recall metrics for both antimicrobial-sensitive and

- 950 Dataset (n=1877 strains). Precision and recall metrics for both antimicrobial-sensitive and 951 antimicrobial-resistant strains were highest using ARDaP (A; range 73-96%) with abritAMR (B; range
- 952 54-62%), AMRFinderPlus (B; range 55-62%) and ResFinder (C; range 42-68%) all performing worse in

953 comparison. To enable comparison with existing AMR prediction software, isolates with intermediate

- 954 AMR were removed prior to analysis. Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP,
- 955 ciprofloxacin; CST, colistin; FEP, cefepime; FQs, fluoroquinolones; IPM, imipenem; MEM, meropenem;
- 956 PIP, piperacillin; TZP, piperacillin/tazobactam; TOB, tobramycin. N.B. Precision (resistance) is also
- 957 known as positive predictive value (PPV) and precision (sensitivity) is also known as negative predictive

958 value (NPV).











Precision (AMR) Recall (AMR) **Precision (sensitivity)** 

Recall (sensitivity)